Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $42 from $52 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect the FDA refusal to file letter for Wakix in idiopathic hypersomnia. Beyond Harmony’s reporting of Q4 results next week, Mizuho looks to the potential of positive Phase 3 data for ZYN-002 in fragile X syndrome as a “rallying point for the story.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Concerns Over Harmony Biosciences: FDA Setback, Patent Risks, and High-Risk Pipeline
- Harmony Biosciences: Buy Rating Affirmed Despite FDA Setback, Strong Growth Potential in Pitolisant Franchise and Pipeline Opportunities
- Strategic Focus on Next-Gen Formulations Supports Buy Rating for Harmony Biosciences Despite Short-term Setbacks
- Harmony Biosciences receives refusal to file letter from FDA for pitolisant
- HRMY Upcoming Earnings Report: What to Expect?